

## Table of Contents

Preface .....	V	<b>4 Different products and their supply chain.....</b>	<b>35</b>
List of abbreviations.....	XIII		
<b>1 The history of cannabis.....</b>	<b>1</b>	<b>4.1 Cultivation and processing of the drug.....</b>	<b>35</b>
1.1 Cannabis in ancient times.....	1	4.1.1 Cannabis physiology .....	35
1.2 Hemp in the Middle Ages.....	1	4.1.2 Standardized and quality assured cannabis flowers.....	36
1.3 Cannabis in 19th century European mainstream medicine .....	4	4.1.3 Plant genetic resources and propagation .....	37
1.3.1 Indian hemp arrives in Europe.....	4	4.1.4 Outdoor cultivation.....	38
1.3.2 A momentous study.....	4	4.1.5 Greenhouse cultivation .....	39
1.3.3 Cannabis becomes established .....	5	4.1.6 Indoor cultivation .....	40
1.3.4 First peak in the 19th century.....	6	4.1.7 Harvest and post-harvest methods .....	41
1.4 Cannabis as a medicinal substance in the 20th century.....	7	4.1.8 Comparison of cultivation systems.....	43
1.4.1 The end of an era .....	7	<b>4.2 Quality standards.....</b>	<b>46</b>
1.4.2 The Renaissance .....	7	4.2.1 Differentiation of substances, preparations and medicinal products.....	46
1.4.3 From Opium Law to Cannabis Law in Germany.....	8	4.2.2 Quality assurance .....	49
1.5 Cannabis as a treatment option in the 21st century .....	8	4.2.3 Quality requirements for cannabis flowers ...	55
<b>2 Botanical description .....</b>	<b>10</b>	4.2.4 Quality requirements for preparations from cannabis flowers .....	64
2.1 Systematics and Taxonomy .....	10	4.2.5 Specific requirements for isolated cannabinoids as active ingredients in medicinal products .....	68
2.2 General botanical characteristics.....	11	4.2.6 Quality requirements for cannabis-based medicinal products.....	71
2.2.1 Habitus, sprout and sex distribution.....	11	4.2.7 Stability studies .....	72
2.2.2 Inflorescences and flowers .....	13	4.2.8 Regulatory aspects of quality control.....	73
2.2.3 Fruits .....	15	<b>4.3 Production of cannabis extracts .....</b>	<b>75</b>
2.3 Cannabis breeding and current cultivars .....	16	4.3.1 Pre- and post-treatment during extraction ..	75
<b>3 Biosynthetic pathways of the cannabinoids .....</b>	<b>18</b>	4.3.2 Extraction with ethanol .....	76
3.1 Cannabinoids.....	18	4.3.3 Extraction with hydrocarbons .....	76
3.1.1 Cannabinoids as chemotaxonomic markers ..	18	4.3.4 Extraction with supercritical carbon dioxide.....	76
3.1.2 Cannabinoid biosynthesis .....	18	4.3.5 Isolation of pure cannabinoids.....	77
3.1.3 Artificial enzymatic production of cannabinoids.....	23	4.3.6 Development of the extraction process.....	78
3.1.4 Chemical synthesis and properties of cannabidiol (CBD).....	26	4.3.7 Validation of the extraction process.....	79
3.1.5 Chemical synthesis and properties of $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC).....	26	<b>4.4 Special considerations for clinical investigational medicinal products.....</b>	<b>80</b>
3.1.6 Chemical synthesis and properties of nabilone.....	28	<b>4.5 Biotechnological production of cannabinoids.....</b>	<b>80</b>
3.2 Terpenes .....	30	4.5.1 Motivation.....	80
3.3 Other secondary substances .....	31	4.5.2 Metabolic engineering.....	81
3.4 Chemotypes of <i>Cannabis sativa</i> .....	32	4.5.3 Challenges for the future .....	83
		<b>5 Supply of medical cannabis.....</b>	<b>87</b>
		5.1 Import from EU and non-EU countries.....	87
		5.1.1 Requirements for import.....	87
		5.1.2 Permit and documentation requirements .....	88
		5.1.3 Organizational processing.....	90

<b>5.2</b>	<b>Cultivation in Germany</b> .....	<b>92</b>	<b>7.5</b>	<b>Neurodegenerative, neuroinflammatory and other neurological diseases</b> .....	<b>144</b>
5.2.1	Prerequisites and legal framework .....	92	7.5.1	Spasticity and paraplegia .....	144
5.2.2	Quality-related requirements for the cultivation of medical cannabis in Germany .....	93	7.5.2	Spasticity in multiple sclerosis .....	144
<b>6</b>	<b>Pharmacological basis of cannabinoid action</b> .....	<b>94</b>	7.5.3	Huntington's chorea .....	144
<b>6.1</b>	<b>The endocannabinoid system</b> .....	<b>94</b>	7.5.4	Epilepsy .....	147
6.1.1	What is the endocannabinoid system? .....	94	7.5.5	Dystonia .....	148
6.1.2	Physiology .....	94	7.5.6	Parkinson's disease .....	148
6.1.3	Disorders of the endocannabinoid system .....	97	<b>7.6</b>	<b>Ophthalmological diseases</b> .....	<b>150</b>
6.1.4	Cannabinoid (CB) receptors .....	98	7.6.1	Glaucoma .....	150
6.1.5	Ligands .....	100	7.6.2	Uveitis .....	151
6.1.6	Biological and biographical differences .....	105	7.6.3	Dry eye .....	151
<b>6.2</b>	<b>Pharmacokinetics and pharmacodynamics of THC and CBD</b> .....	<b>110</b>	<b>7.7</b>	<b>Psychiatric disorders</b> .....	<b>152</b>
6.2.1	THC .....	110	7.7.1	Dementia .....	152
6.2.2	Cannabidiol (CBD) .....	113	7.7.2	Gilles de la Tourette syndrome .....	156
<b>6.3</b>	<b>Entourage effect</b> .....	<b>115</b>	7.7.3	ADHD .....	159
6.3.1	Entourage effect in the ECS .....	115	7.7.4	Obsessive compulsive disorder .....	160
6.3.2	Entourage effect due to secondary cannabis ingredients .....	116	7.7.5	Anxiety disorders .....	161
<b>7</b>	<b>Medical applications and their evidence</b> .....	<b>120</b>	7.7.6	Affective disorders .....	163
<b>7.1</b>	<b>General information on dosage and dose finding</b> .....	<b>120</b>	7.7.7	Post-traumatic stress disorder .....	164
7.1.1	Start of treatment .....	120	7.7.8	Psychosis .....	165
7.1.2	Type of use .....	121	7.7.9	Autism spectrum disorder .....	166
7.1.3	Dosage titration .....	122	<b>7.8</b>	<b>Skin disorders</b> .....	<b>172</b>
7.1.4	Application frequency and distribution throughout the day .....	122	7.8.1	Endocannabinoid system of the skin .....	173
<b>7.2</b>	<b>Chronic pain</b> .....	<b>123</b>	7.8.2	Wound treatment .....	175
7.2.1	Preclinical findings .....	123	7.8.3	Modulation of the skin barrier .....	176
7.2.2	Clinical findings and evidence .....	124	7.8.4	Atopic dermatitis .....	176
7.2.3	Dosage .....	128	7.8.5	Pruritus .....	178
7.2.4	Tolerability and safety .....	129	7.8.6	Allergic contact dermatitis (ACD) .....	178
<b>7.3</b>	<b>Nausea, vomiting, appetite stimulation</b> .....	<b>132</b>	7.8.7	Acne vulgaris .....	179
7.3.1	Definitions .....	132	7.8.8	Epidermolysis bullosa (EB) .....	179
7.3.2	Hypothesis of mechanism of action for cannabinoids .....	132	7.8.9	Pyoderma gangrenosum .....	179
7.3.3	Nausea and vomiting .....	132	7.8.10	Psoriasis .....	180
7.3.4	Appetite stimulation and cachexia .....	133	7.8.11	Skin cancer .....	180
7.3.5	Conclusion .....	134	7.8.12	Conclusion .....	181
<b>7.4</b>	<b>Gastroenterological diseases</b> .....	<b>135</b>	<b>8</b>	<b>Cannabis as a stimulant</b> .....	<b>185</b>
7.4.1	Inflammatory bowel disease (Crohn's disease and ulcerative colitis) .....	135	<b>8.1</b>	<b>Model projects on cannabis</b> .....	<b>185</b>
7.4.2	Irritable Bowel Syndrome .....	137	8.1.1	Application from Berlin .....	185
			8.1.2	Application from Schleswig-Holstein .....	185
			8.1.3	Renewed application from Berlin .....	186
			<b>8.2</b>	<b>Consequences of cannabis use</b> .....	<b>187</b>
			8.2.1	Cannabis intoxication .....	187
			8.2.2	Abuse, dependence, concomitant use, scene entry .....	187
			8.2.3	Other cannabis-related disorders .....	190
			8.2.4	Trigger factors and consequences of legalization .....	193

<b>8.3</b>	<b>Comparison to other stimulants and addictive substances (alcohol, caffeine, nicotine, heroin etc.)</b> .....	<b>198</b>	<b>10.2</b>	<b>Regulatory framework at European level</b> .....	<b>230</b>
8.3.1	Alcohol .....	198	10.2.1	Possibilities for placing on the market on the basis of a formal authorization.....	231
8.3.2	Nicotine (smoking) .....	200	10.2.2	Possibilities for placing on the market without formal authorization .....	231
8.3.3	Heroin .....	201	<b>10.3</b>	<b>Legal basis and availability of cannabis abroad (EU, non-EU)</b> .....	<b>232</b>
8.3.4	Comparison with cannabis.....	202	10.3.1	The Netherlands.....	232
<b>9</b>	<b>Risks associated with the medical use of cannabis</b> .....	<b>205</b>	10.3.2	Italy .....	232
<b>9.1</b>	<b>Adverse drug reactions (ADRs)</b> .....	<b>205</b>	10.3.3	United Kingdom .....	233
9.1.1	THC and other CB1 agonists .....	205	10.3.4	Denmark.....	233
9.1.2	CBD .....	209	10.3.5	Israel .....	233
9.1.3	Extracts and flowers .....	210	10.3.6	Canada .....	234
<b>9.2</b>	<b>Interactions with cannabinoids</b> .....	<b>212</b>	10.3.7	Australia .....	234
9.2.1	THC and other CB1 agonists .....	212	10.3.8	Columbia .....	235
9.2.2	CBD .....	213	10.3.9	United States of America .....	235
9.2.3	Interactions between CBD and THC .....	213	<b>10.4</b>	<b>Legal framework in Germany</b> .....	<b>237</b>
9.2.4	Extracts and flowers .....	214	10.4.1	Narcotics Act (Betäubungsmittelgesetz, BtMG).....	237
9.2.5	Pharmacology-based guidance on the safe use of cannabis-based medicinal products ..	214	10.4.2	Narcotics Foreign Trade Ordinance (Betäubungsmittel-Außenhandelsverordnung, BtMAHV).....	238
<b>9.3</b>	<b>Contraindications</b> .....	<b>215</b>	10.4.3	Narcotics Prescription Ordinance (Betäubungsmittel-Verschreibungsverordnung, BtMVV) .....	238
9.3.1	THC and other CB1 agonists .....	215	10.4.4	Fifth Book of the German Social Code (SGB V).....	239
9.3.2	CBD .....	216	<b>10.5</b>	<b>Structure and function of the Cannabis Agency</b> .....	<b>239</b>
<b>9.4</b>	<b>Tolerance and addiction or dependence</b> .....	<b>217</b>	10.5.1	Legal basis.....	239
9.4.1	THC and other CB1 agonists .....	217	10.5.2	Development of the Cannabis Agency.....	240
9.4.2	CBD .....	218	10.5.3	Responsibilities and monitoring.....	241
<b>9.5</b>	<b>Impairment of driving safety</b> .....	<b>218</b>	<b>10.6</b>	<b>Authorization for medical use</b> .....	<b>242</b>
9.5.1	Pharmacokinetics .....	219	10.6.1	(Social) medical requirements .....	242
9.5.2	Effects relevant for traffic .....	219	10.6.2	Documents required .....	244
9.5.3	Analytical methods for detection of cannabinoids in biological material and their interpretation .....	220	10.6.3	Course of the approval procedure.....	244
9.5.4	Legal regulations .....	221	10.6.4	Conclusion.....	246
9.5.5	Penalty thresholds in international comparison .....	221	<b>10.7</b>	<b>Companion survey/scientific project</b> .....	<b>247</b>
9.5.6	Prevalence and risk identification.....	222	<b>11</b>	<b>Legal status of medicinal cannabis and cannabinoids in Germany</b> .....	<b>252</b>
9.5.7	Outlook.....	223	<b>11.1</b>	<b>Definitions of terms: active substance, medicinal product, proprietary medicinal product</b> .....	<b>252</b>
<b>10</b>	<b>Legal framework for the use of cannabis</b> .....	<b>225</b>	<b>11.2</b>	<b>Cannabis-based proprietary medicinal products</b> .....	<b>253</b>
<b>10.1</b>	<b>International agreements</b> .....	<b>225</b>	<b>11.3</b>	<b>Cannabis-based prescription drugs</b> .....	<b>254</b>
10.1.1	Single Convention on Narcotic Drugs, 1961 ...	227			
10.1.2	Convention on Psychotropic Substances, 1971 .....	228			
10.1.3	United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988.....	229			

<b>12</b>	<b>Legal status of cannabis and cannabinoids in non-medical products</b> .....	<b>256</b>		
<b>12.1</b>	<b>CBD and cannabis preparations in foodstuffs and nutritional supplements</b> .....	<b>256</b>		
12.1.1	Food .....	256		
12.1.2	Food supplements .....	260		
12.1.3	Flavorings .....	262		
12.1.4	CBD products as medicinal products by function or presentation .....	262		
<b>12.2</b>	<b>CBD and cannabis preparations in medical devices</b> .....	<b>265</b>		
<b>12.3</b>	<b>CBD and cannabis preparations in cosmetics</b> .....	<b>266</b>		
<b>12.4</b>	<b>CBD and cannabis preparations in smoking products</b> .....	<b>267</b>		
<b>13</b>	<b>Medicinal Cannabis: Case studies from selected European countries</b> .....	<b>269</b>		
<b>13.1</b>	<b>Czech Republic</b> .....	<b>269</b>		
<b>13.2</b>	<b>France</b> .....	<b>270</b>		
13.2.1	Beginnings .....	270		
13.2.2	Main objectives .....	272		
13.2.3	Experimental framework .....	272		
13.2.4	Patients' involvement .....	272		
13.2.5	Category of medications offered to patients within the scope of the study .....	273		
13.2.6	Call for applications .....	273		
13.2.7	Selected suppliers .....	275		
13.2.8	Approved medications .....	275		
13.2.9	Supply and distribution .....	276		
<b>13.3</b>	<b>Greece</b> .....	<b>279</b>		
<b>13.4</b>	<b>Italy</b> .....	<b>280</b>		
<b>13.5</b>	<b>Malta</b> .....	<b>281</b>		
<b>13.6</b>	<b>Poland</b> .....	<b>282</b>		
13.6.1	Magistral preparations .....	283		
13.6.2	Compounding .....	284		
13.6.3	Pharmaceutical raw material .....	285		
13.6.4	Dosage forms of magistral preparations .....	285		
13.6.5	Extemporaneous medicine of medical cannabis in Poland .....	286		
<b>13.7</b>	<b>Portugal</b> .....	<b>287</b>		
<b>13.8</b>	<b>Switzerland</b> .....	<b>290</b>		
13.8.1	Legal framework .....	290		
13.8.2	Authorization procedures in Switzerland .....	292		
13.8.3	Ready-to-use cannabis-based medicinal products authorized in Switzerland .....	293		
<b>13.9</b>	<b>United Kingdom</b> .....	<b>295</b>		
13.9.1	Medical cannabis .....	295		
13.9.2	CBD consumer products .....	297		
<b>14</b>	<b>Forms and methods of administration</b> .....	<b>300</b>		
<b>14.1</b>	<b>Dosage forms for medical use</b> .....	<b>300</b>		
14.1.1	Tablets .....	300		
14.1.2	Capsules .....	302		
14.1.3	Decoctions („tea“) .....	302		
14.1.4	Oil .....	304		
14.1.5	Oromucosal spray .....	310		
14.1.6	Inhalants .....	311		
14.1.7	Suppositories .....	318		
14.1.8	Transdermal therapeutic systems and semi-solid dermatics .....	320		
14.1.9	Parenterals .....	320		
14.1.10	Eyedrops .....	321		
14.1.11	Edibles .....	322		
<b>14.2</b>	<b>Forms of consumption in recreational use</b> .....	<b>331</b>		
14.2.1	Marijuana .....	335		
14.2.2	Solventless concentrates .....	336		
14.2.3	Solvent-using concentrates .....	340		
14.2.4	Cannabis tinctures .....	343		
14.2.5	Foods containing cannabis .....	344		
14.2.6	Synthetic cannabinoids .....	346		
<b>14.3</b>	<b>Types of administration in recreational use</b> .....	<b>348</b>		
14.3.1	Joints, spliffs and blunts .....	349		
14.3.2	Chillums, one-hitters, pipes .....	351		
14.3.3	Hookahs and bongs .....	351		
14.3.4	Bucket smoking .....	353		
14.3.5	Hot knives (spots) .....	354		
14.3.6	Glass smoking or hot needles .....	354		
14.3.7	Vaping .....	354		
14.3.8	Dabbing .....	356		
<b>15</b>	<b>Compounding of medicinal products containing cannabinoids in the pharmacy</b> .....	<b>358</b>		
<b>15.1</b>	<b>Legal framework</b> .....	<b>358</b>		
15.1.1	Magistral preparations (Rezepturarzmittel) .....	358		
15.1.2	Officinal medicinal product (Defekturarzneimittel) .....	358		
<b>15.2</b>	<b>Manufacturing documentation</b> .....	<b>360</b>		
15.2.1	Manufacturing instructions .....	360		
15.2.2	Manufacturing protocol .....	361		

<b>15.3 Starting material testing</b> .....	<b>361</b>	15.8.2 Specifics of cannabis price calculation .....	445
15.3.1 Legal framework and testing obligations .....	361	15.8.3 Rounding rules for price calculation .....	447
15.3.2 Starting materials without a certificate of analysis .....	361	15.8.4 Special PZN for magistral preparations containing cannabinoids .....	447
15.3.3 Starting materials with a certificate of analysis .....	362	15.8.5 Determining the most economical package or package size combination .....	448
15.3.4 Test methods .....	364	15.8.6 Imported cannabis flowers in unchanged form .....	448
15.3.5 Documentation obligation .....	364	15.8.7 Imported cannabis flowers in preparations ..	448
<b>15.4 Available starting materials and sources of supply</b> .....	<b>364</b>	15.8.8 Cannabis flowers from German cultivation ...	450
15.4.1 Flowers .....	364	15.8.9 Cannabis extracts in unchanged state .....	450
15.4.2 Extracts .....	365	15.8.10 Cannabis extracts in preparations .....	451
15.4.3 Cannabinoids .....	372	15.8.11 Dronabinol in preparations .....	451
15.4.4 Special characteristics of manufacturing sets .....	373	15.8.12 Cannabidiol in preparations .....	451
<b>15.5 Testing of starting materials for cannabis flowers, cannabis extracts and cannabinoids</b> .....	<b>374</b>	<b>16 Supply of cannabis prescriptions in the pharmacy</b> .....	<b>458</b>
15.5.1 Cannabis flowers .....	374	<b>16.1 Legal framework</b> .....	<b>458</b>
15.5.2 Extracts .....	383	16.1.1 General formalities of the regulation of narcotics .....	458
15.5.3 Dronabinol .....	384	16.1.2 Maximum quantities in the prescription of cannabis medicinal products .....	459
15.5.4 CBD .....	390	16.1.3 Specific features of the prescription of cannabis medicinal products .....	459
15.5.5 Combined test systems discriminating THC or CBD-dominant and equilibrated starting materials .....	394	16.1.4 Prescription drugs .....	465
<b>15.6 Manufacture of magistral preparations</b> .....	<b>399</b>	16.1.5 Proprietary medicinal products .....	465
15.6.1 Weighing correction .....	400	16.1.6 Non-availability .....	468
15.6.2 Plausibility check .....	403	16.1.7 Drug substitution in cannabis preparations ..	468
15.6.3 Important processing aspects for standardized cannabis formulations .....	409	16.1.8 Discount agreements for cannabis medicinal products .....	470
15.6.4 Child-resistant packaging .....	420	16.1.9 Obligation to check for cost coverage by statutory health insurance .....	471
15.6.5 Baking mixtures .....	421	16.1.10 Individual imports in accordance with Section 73(3) of the German Medicinal Products Act .....	471
15.6.6 Production of flower or extract mixtures with defined THC and CBD contents .....	424	<b>16.2 Special features of pharmacy logistics when handling medicinal products containing cannabis</b> .....	<b>472</b>
<b>15.7 Preparation of officinal medicinal products</b> .....	<b>431</b>	16.2.1 Storage .....	472
15.7.1 Test instructions for officinal medicinal products .....	431	16.2.2 Cannabis in mail order and courier service ...	473
15.7.2 Test protocol for officinal medicinal products .....	431	16.2.3 Transfer of narcotic drugs containing cannabinoids between pharmacies .....	474
15.7.3 Risk-based tiered model for final analytical testing .....	432	16.2.4 Returns of narcotics containing cannabinoids .....	475
15.7.4 Application of the risk-based tiered model to medicinal products containing cannabis or cannabinoids .....	435	16.2.5 Dealing with quality defects .....	475
<b>15.8 Price calculation</b> .....	<b>445</b>	16.2.6 Withdrawal of narcotics containing cannabinoids by pharmacies .....	476
15.8.1 Basic principles of price calculation for compounded preparations .....	445	16.2.7 Destruction of narcotics containing cannabinoids .....	476

<b>17 Narcotics documentation</b> .....	<b>479</b>	17.3.6 Prescription of cannabis-based proprietary medicinal products .....	493
<b>17.1 Legal basis</b> .....	<b>479</b>	<b>18 Important considerations for counseling cannabis patients</b> .....	<b>498</b>
<b>17.2 General documentation requirements for narcotics</b> .....	<b>479</b>	<b>18.1 General instructions for use</b> .....	<b>498</b>
17.2.1 Import and export of narcotics (Section 11 of the Narcotics Act) .....	480	<b>18.2 Instructions for use specific to the dosage form or mode of administration</b> .....	<b>498</b>
17.2.2 Dispensing and acquisition of narcotics (Section 12 of the Narcotics Act) .....	480	<b>18.3 Vaporization</b> .....	<b>498</b>
17.2.3 Dispensing narcotics on the basis of a prescription (Section 13 of the Narcotics Act) .....	482	18.3.1 Filling dosing capsules .....	498
17.2.4 Labeling according to Section 17 of the Narcotics Act and Section 14 of the Ordinance on the Prescription of Narcotics ...	483	18.3.2 Volcano Medic 2 .....	500
17.2.5 Destruction of narcotics according to Section 16 of the Narcotics Act .....	484	18.3.3 Mighty Medic or Mighty+ Medic .....	500
17.2.6 Reporting according to Section 18 of the Narcotics Act .....	484	<b>18.4 Dosing</b> .....	<b>501</b>
<b>17.3 Special features of narcotics documentation for prescription medicinal products containing cannabis</b> .....	<b>485</b>	<b>18.5 Cannabis patients and driving</b> .....	<b>505</b>
17.3.1 Narcotics documentation specific to variety/ extract .....	485	<b>18.6 Traveling with cannabis</b> .....	<b>506</b>
17.3.2 Formulation production and documentation .....	487	18.6.1 Traveling within the Schengen area .....	506
17.3.3 Excess consumption .....	489	18.6.2 Traveling outside the Schengen area .....	506
17.3.4 Weighing gain, weighing loss and overfill .....	492	18.6.3 Carrying of cannabis medicinal products by physicians .....	509
17.3.5 Mishaps during production .....	492	<b>18.7 Hunting license</b> .....	<b>509</b>
		<b>18.8 Recognizing abuse and dealing with suspected misuse</b> .....	<b>509</b>
		<b>Photo credits</b> .....	<b>513</b>
		<b>Subject index</b> .....	<b>517</b>
		<b>The editor</b> .....	<b>535</b>
		<b>The authors</b> .....	<b>536</b>